Zoo Miami mourns loss of 17-year-old lion Jabari
Jabari, a 17-year-old male lion, was known for leading a pride and fathering cubs.
For several years, Jabari suffered from chronic arthritis, primarily in his upper spine, which restricted his mobility and comfort, officials said.
Despite extensive treatments to manage pain and maintain his quality of life, the lion's condition deteriorated recently, leaving euthanasia as the only humane option.
Officials said that at nearly 18, Jabari surpassed the typical lifespan of a male lion in the wild, which rarely exceeds 12 years.
Jabari arrived at Zoo Miami in November 2008 from the Racine Zoo in Wisconsin, alongside his brother, Kwame.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Sarepta can begin shipping Elevidys therapy after FDA reverses pause, stock soars
Sarepta (SRPT) will begin shipping its top-selling muscular dystrophy therapy, Elevidys, after the U.S. Food and Drug Administration (FDA) reversed its request for a voluntary pause late Monday. The news sent Sarepta's stock up sharply. The company extended gains Tuesday, with its stock up more than 40% in pre-market action. Sarepta had been trading down nearly 90% year-to-date after four patient deaths, and FDA probe and a European Medicines Agency panel recommending rejection of Elevidys pressured the company last week. "We are very pleased that FDA chose to rapidly and comprehensively complete that review and to recommend that we remove our voluntary pause and resume shipment of Elevidys for ambulatory patients," said Sarepta CEO Doug Ingram, in a statement Monday. The FDA will continue to investigate the patient deaths, the latest of which was a 51-year-old patient in a clinical trial for a different muscular dystrophy drug. There was also an 8-year-old boy in Brazil, who died on June 7 from a different drug. There have been two Elevidys patient deaths reported this year. Analysts are cautiously optimistic about the shipments resuming, but are waiting to see the impact to the bottom line. The company has needed to continue strong sales of Elevidys in order to clear its $1.5 billion convertible debt due in 2027. "It seems like the FDA is listening to the community and this is great news for patients, but we remain on the sidelines until we gain better visibility into how demand trends, which is important from a balance sheet perspective," wrote Leerink Partners analyst Joseph Schwartz in a note to clients Monday. Jefferies analyst Andrew Tsai, one of the few which had maintained a Buy rating on the stock, said his firm did not doubt the company's ability to get the product back on the market, and is now watching how sales follow. "We were already unsure whether FDA could pull our premise was that Elevidys stays on the market ... though we also acknowledge Elevidys' sales outlook was looking murkier when SRPT went against the FDA's wishes (i.e. hospitals were starting to pause dosing)," Tsai wrote. "If SRPT's internal stress tests of the... franchise 'flooring' at $1.4B annually into the Street might have greater confidence in SRPT's ability to pay off the $1.1B+ of converts in 2027," he added. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Postbiotics Market worth $224.8 million by 2030- Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., July 29, 2025 /PRNewswire/ -- According to MarketsandMarkets™, The postbiotics market is estimated at USD 146.7 million in 2025 and is projected to reach USD 224.8 million by 2030, at a CAGR of 8.9%, from 2025 to 2030. The demand for postbiotics is projected to rise significantly, driven by growing consumer interest in microbiome health and the inherent limitations of probiotics and prebiotics in terms of viability and stability. Postbiotics, composed of non-living microbial cells and metabolites, offer proven health benefits without the need for live microorganisms. Their high stability under extreme processing conditions makes them ideal for a wide range of product formulations, including shelf-stable dietary supplements, functional foods, and beverages. Heat-treated bacterial strains, most notably Lactobacillus and Bifidobacterium, are widely recognized for their safety and scientifically supported benefits in gut, immune, and skin health. As consumer demand for microbiome-friendly solutions continues to grow, postbiotics are well-positioned to capture a larger share of the biotics market. Browse in-depth TOC on "postbiotics Market" 250– Tables30– Figures200– Pages Download PDF Brochure: Postbiotics in dry form to account for the fastest growth during the forecast period Postbiotic powders are versatile forms and attractive to consumers; they are expected to be the most rapidly growing during the forecast period because postbiotic powders offer a highly concentrated dose of bioactive compounds that can be easily incorporated into multiple food and drink formats such as smoothies, cereals, and snack bars-a boon for modern lifestyles with taste and convenience intact. From a manufacturing perspective, their dry, heat-stable nature makes it easy to process them without major modifications to existing equipment or product systems. In addition, the increasing disillusionment of consumers with conventional pills has made powders, gummies, and bars alternative delivery formats all the more popular. Although live probiotics may fail in such formats, postbiotics overcome this hurdle, much more so in dry form, making them the best solution for the manufacturers as well as health-conscious consumers. This combination of formulation ease, shelf stability, and growing end-user preference underlines why dry form postbiotics are expected to witness the steepest growth in future years. Cosmetics and personal care products segment to hold greater market share during the forecast period The trend of skinimalism increasingly embraces everything simple and multifunctional in skincare, thereby rapidly increasing the demand for postbiotics. Postbiotics address numerous benefits within a singular formulation. They have been introduced into cosmetics such as moisturizing creams intended to restore the hydrolipid barrier, anti-aging serums, and hair care containing agents that strengthen the scalp and improve hair condition. Coupling their multifunctionality with safety and stability makes postbiotics suitable for sensitive, acne-prone, or otherwise problematic skin. They do not pose the risk of microbial overgrowth as live probiotics do, making them ideal for products aimed at restoring the skin's natural microbiome balance. With increasing eco-awareness and health-consciousness among consumers, and as interest rises in Clean Beauty and microbiome-friendly skincare, especially into 2025, postbiotics are expected to establish themselves as the active ingredient of choice within modern beauty. The anti-inflammatory, antioxidant, and barrier-supporting qualities of postbiotics thus enhance their efficacy and safety and have driven the postbiotic to ever-rising prominence in next-generation cosmetics and personal care products. Request Sample Pages: European region to hold a significant market share in the global postbiotics market Most of the European consumers now claim to use dietary supplements, which reveals the growing trend toward preventive health and wellness. Growing consumer engagement creates a conducive environment for the postbiotic markets as people turn to scientifically validated, gut-friendly sources for postbiotics that can be easily incorporated into daily routines through supplements and functional foods. Active participation of the major regional players with respect to Associated British Foods plc (UK), can also be the reason of European postbiotic growth. In November 2023, AB Biotek Human Nutrition & Health (UK), subsidiary of ABF (UK) sealed a partnership deal with Tetra Pak (Switzerland) to come up with innovative postbiotic solutions for food & beverage, making it easy to incorporate postbiotics into mainstream products such as dairy, plant-based drinks, and snacks without any special equipment for their manufacturing. Such partnerships widen the simplicity of the formulation of products and visibility and accessibility of postbiotic-enriched offerings. With this innovation, seen by one of the dominant European players, ABF (UK), bringing postbiotics closer to consumers through the most consumed formats, public awareness is anticipated to grow quickly, and the market is expected to expand across the region. The report profiles key players such as Cargill, Incorporated (US), ADM (US), Kerry Group PLC (Ireland), dsm-firmenich (Netherlands), Associated British Foods plc (UK), BASF (Germany), Novozymes A/S, part of Novonesis Group (Denmark), International Flavors & Fragrances Inc (US), MCLS Europe B.V. (Netherlands), Phileo by Lesaffre (France), Lallemand Inc. (Canada), Sami-Sabinsa Group. (India), CJ CheilJedang Corp. (South Korea), Biotenova Sdn. Bhd. (Malaysia), and Bioprox Healthcare (France). Get 10% Free Customization on this Report: Browse Adjacent Reports @ Food and Beverage Market Research Reports & Consulting Related Reports: Functional Food Ingredients Market by Type (Probiotics, Protein & Amino Acids, Phytochemicals & Plant Extracts, Prebiotics, Omega-3 Fatty Acids, Carotenoids, Vitamins), Application, Source, Form, Health Benefits and Region - Global Forecast to 2029 Probiotics Market Size, Share, Analysis, & Growth Trends Report by Product Type (Functional Food & Beverages (FnB), Dietary Supplements, and Feed), Ingredient (Bacteria and Yeast), End User (Human and Animal), Distribution Channel and Region - Global Forecast to 2029 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets Inc.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Insight: Our Website: Source: Logo: View original content: SOURCE MarketsandMarkets
Yahoo
8 minutes ago
- Yahoo
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
FRIENDSWOOD, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025, at 12:30 p.m. Eastern time. A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at A replay of the webcast will be available following the conclusion of the live broadcast. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Investor Contact:Camilla Zuckeroczuckero@ Media Contact:Allison Marshallamarshall@ Source: Castle Biosciences while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
